|
Day Two November 19
| 7:45
One-to-One Meetings and Morning Coffee |
|
8:15 Chairperson's Remarks
8:30 Complementing Internal R&D with External Innovation - Partnering with Both Emerging and Mature Biotech Companies
Creating the right balance in your portfolio of alliances
Weighing the risk and rewards of each partnership
Integrating your licensing initiatives with your portfolio and R&D
Ron Newbold, Ph.D., Senior Director, Strategic Research Initiatives, External Scientific Affairs, Merck & Co.
9:15 Maintaining and Extending a Franchise's Life Cycle
Available product exclusivity periods and how to get them
How in-licensed improvements can add significant value to a franchise
Protecting the franchise against generics
Martin Voet, Senior Vice President and Chief IP Counsel, Allergan, Inc
|
10:00 One-to-One Meetings and Networking Refreshment Break
|
|
10:45 A Big Pharma Perspective: Properly Managing Intellectual Property in Licensing Transactions
Evaluating the scope of license grants (field of use, etc.)
Preserving rights to pre-existing IP
Negotiating ownership and rights to new IP arising in connection with the license
Planning rights after expiration or termination of the license
Non-compete clauses
Allocating responsibility for patents and other IP related issues
Paul Thompson, Ph.D., Senior Legal Director, Licensing, Schering-Plough Corporation
11:30 Providing For Patent Issues in The License Agreement
Inventorship and ownership of improvements
Control of patent prosecution
Rights of other licensees in field limited licenses
Providing for patent term extensions
Enforcement mechanisms
Addressing third party patent issues
Beth Arnold, Partner, Foley Hoag, LLP
|
12:15 One-to-One Meetings and Networking Luncheon
|
|
2:00 The Impact of Deals in Asia: Japan and Beyond
Why partner potential blockbusters
What benefit does a partner bring to the asset?
What needs be present to make this successful?
Michael J. Haugh, Corporate Business Development, Eli Lilly and Company
2:45 The Partner of Choice: What Qualities and Technologies are Biotech Companies Seeking in a Partner?
Constantine Chinoporos, Senior Director Corporate Development, Genzyme
3:30 A Biotech Perspective: Using Strategic Collaborations to Build Long Term Value
David L. Snitman, Ph.D., Chief Operating Officer and Vice President, Business Development, Array BioPharma Inc.
4:15 Driving Performance Through In-licensing: Findings from McKinsey's
2003-2004 cross-sector licensing benchmarking survey
Best practice in-licensors have unique processes for scouting, deal making
and alliance management. In this session we present our study findings,
which reveal some important characteristics common to high performers.
Meagan Dietz and Jeff Elton, McKinsey & Co.
4:45 Close of Executive Forum
These Pharmaceutical Strategy Series meetings have been quite successful, both in terms of attracting quality speakers and generating a good audience turnout from the pharmaceutical industry.
- James Resch, Ph.D, Director, Strategic Planning, Global Discovery Affairs, AstraZeneca
|
